I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Soumerai, J. D.
224
results:
Articles (Online) X
Search for persons
X
Sorted by: Relevance
Sorted by: Year
?
1
LONG‐TERM FOLLOW‐UP OF MULTICENTER PHASE II TRIAL OF ZANUBR..:
Soumerai, J. D.
;
Dogan, A.
;
Seshan, V.
...
Hematological Oncology. 41 (2023) S2 - p. 233-235 , 2023
Link:
https://doi.org/10.1002/..
?
2
REAL‐WORLD OUTCOMES OF PATIENTS (PT) WITH RELAPSED OR REFRA..:
Soumerai, J.
;
Wang, L.
;
Gu, F.
..
Hematological Oncology. 41 (2023) S2 - p. 733-734 , 2023
Link:
https://doi.org/10.1002/..
?
3
P06.11.B NEUROTOXICITY AND MANAGEMENT OF PRIMARY AND SECOND..:
Karschnia, P
;
Arrillaga-Romany, I C
;
Eichler, A
...
Neuro-Oncology. 25 (2023) Supplement_2 - p. ii47-ii48 , 2023
Link:
https://doi.org/10.1093/..
?
4
PATTERNS OF IMMUNOGLOBULIN G TESTING AND INFECTION OUTCOMES..:
Soumerai, J. D.
;
Yousif, Z.
;
Gift, T.
...
Hematological Oncology. 41 (2023) S2 - p. 744-745 , 2023
Link:
https://doi.org/10.1002/..
?
5
LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN R/R CHRONIC LYMPHOCY..:
Siddiqi, T.
;
Maloney, D. G.
;
Kenderian, S. S.
...
Hematological Oncology. 41 (2023) S2 - p. 60-62 , 2023
Link:
https://doi.org/10.1002/..
?
6
P687: A PHASE 1 STUDY WITH THE NOVEL B-CELL LYMPHOMA 2 (BCL..:
Opat, S.
;
Cheah, C. Y.
;
Lasica, M.
...
HemaSphere. 6 (2022) - p. 583-584 , 2022
Link:
https://doi.org/10.1097/..
?
7
P1114: ZANDELISIB ON INTERMITTENT DOSING AS A SINGLE AGENT ..:
Soumerai, J. D.
;
Jagadeesh, D.
;
Salman, H.
...
HemaSphere. 6 (2022) - p. 1004-1005 , 2022
Link:
https://doi.org/10.1097/..
?
8
ZANDELISIB, A PI3Kδ INHIBITOR ON INTERMITTENT SCHEDULE (IS)..:
Pagel, J.
;
Reddy, N.
;
Jagadeesh, D.
...
Hematological Oncology. 39 (2021) S2 - p. , 2021
Link:
https://doi.org/10.1002/..
?
9
TRANSCEND CLL 004: MINIMAL RESIDUAL DISEASE AFTER LISOCABTA..:
Siddiqi, T.
;
Dorritie, K.A.
;
Soumerai, J.D.
...
Hematological Oncology. 37 (2019) S2 - p. 109-110 , 2019
Link:
https://doi.org/10.1002/..
?
10
THE PI3Kδ INHIBITOR ME‐401 ± RITUXIMAB IN RELAPSED/REFRACTO..:
Zelenetz, A.D.
;
Jagadeesh, D.
;
Kenkre, V.P.
...
Hematological Oncology. 37 (2019) S2 - p. 176-177 , 2019
Link:
https://doi.org/10.1002/..
?
11
ME‐401, A NOVEL, ORAL, POTENT AND SELECTIVE INHIBITOR OF PH..:
Ghalie, R.G.
;
Pagel, J.M.
;
Soumerai, J.
...
Hematological Oncology. 35 (2017) S2 - p. 407-407 , 2017
Link:
https://doi.org/10.1002/..
?
12
TIME FROM DIAGNOSIS TO 2ND TREATMENT IS A PROMISING SURROGA..:
Soumerai, J.D.
;
Ni, A.
;
Batlevi, C.
...
Hematological Oncology. 35 (2017) S2 - p. 230-230 , 2017
Link:
https://doi.org/10.1002/..
?
13
DEFINING PROGRESSION FREE SURVIVAL AFTER MULTIPLE LINES OF ..:
Batlevi, C.
;
Alperovich, A.
;
Ni, A.
...
Hematological Oncology. 35 (2017) S2 - p. 229-230 , 2017
Link:
https://doi.org/10.1002/..
?
14
A535 Phase II Trial of Bortezomib and Rituximab in Relapsed..:
Ghobrial, IM
;
Roccaro, AM
;
Matous, J
...
Clinical Lymphoma and Myeloma. 9 (2009) - p. S83-S84 , 2009
Link:
https://doi.org/10.1016/..
?
15
A533 RAD001: Phase II Trial in Relapsed/Refractory Waldenst..:
Ghobrial, IM
;
Roccaro, AM
;
Chuma, S
...
Clinical Lymphoma and Myeloma. 9 (2009) - p. S82-S83 , 2009
Link:
https://doi.org/10.1016/..
1-15